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Carcinogenesis is recognized as a multistep process.
It occurs over a relative long span of time,
which offers intervention opportunities for cancer
prevention [1]. Using drugs to prevent cancer rather
than treat cancer is the major research goal in the
field of ‘chemoprevention’. Tremendous research
efforts have been devoted toward using natural,
synthetic or biological agents to prevent, suppress
or delay the initiation and or the progression of
premalignant cells to cancer [1]. However a big
challenge for effective cancer prevention is to
identify chemoprevention agents with demonstrable
efficacy and safety for healthy general population
[2].
The process of carcinogenesis requires a series of
genetic/epigenetic changes that transform normal
cells to premalignant cells, then to malignant cells,
and finally in some cases to metastatic cells [3]. With
our exponentially increased knowledge of cancer
genome landscapes via next generation sequencing
technologies, it has been increasingly recognized
that an important way to potentially reduce cancer
deaths in the future is to improve cancer prevention
based on our understanding of the cancer genomic
information [4]. Cancer treatment is in the process
of evolving from the conventional ‘one-size-fits-
all’ approach to a personalized approach, in which
patients are treated according to their genetic
makeup. Can we conduct personalized cancer
prevention with chemopreventive agents based on
the genetic risk factors in population? The answer
to this question requires the discovery of targeted
cancer prevention strategies that can selectively
eradicate premalignant cells with minimal toxicity to
normal tissues by targeting the genetic vulnerability
in premalignant cells.
Synthetic lethality is one of the most
promising approaches for developing targeted
cancer prevention strategy. Synthetic lethality
involves he genetic interaction between two genes
and pathways. The inhibition of either gene or
pathway alone has no effect on cell viability, but
the simultaneous inhibition of both genes or both
pathways lead to cell death [5]. The goal of using
synthetic lethality as a targeted cancer prevention
approach is to identify agents that specifically kill
premalignant cells with defined genetic alterations
while leaving normal healthy cells unaffected. A
recent study demonstrated the feasibility, efficacy
and potential tolerability of this synthetic lethality
approach for colorectal cancer chemoprevention in
an in vivo preclinical setting [6].
Adenomatous polyposis coli (APC) is a tumor
suppressor protein. Germ line mutations of this gene
cause a premalignant disease, familial adenomatous
polyposis (FAP), which usually becomes malignant.
Thus it is of clinical importance to develop effective
chemopreventive strategies for patients with APC
mutations and FAP. In a recent study, combination
of TNF-related apoptosis-inducing ligand (TRAIL) and
retinyl acetate (RAc) leads to a synthetic lethality
in APC -deficient intestinal adenoma cells [6]. In
normal cells high expression of cellular FLICE-like
inhibitory protein (c-FLIP) forms an internal block
for TRAIL-induced apoptosis. APC protein acts as a
negative regulator of the Wnt signaling pathway,
which is involved in multiple cellular functions
including transcriptional activation, cell migration
and adhesion and apoptosis. In APC-deficient
premalignant cells, β-catenin, a major player of the
Wnt signaling pathway is activated. Activation of β-
catenin leads to a decrease of c-FLIP expression,
which eliminates the internal block on the TRAIL
pathway. Thus APC deficiency removes a critical
block for TRAIL and RAC-induced apoptosis, which
results in a synthetic lethal interaction between
TRAIL/RAC and APC deficiency in premalignant cells
[6]. Later a similar concept was tested in mutant
KRAS premalignant cells, which contain reduced c-
2FLIP expression [7]. These studies provide a proof-
of principle that synthetic lethality can be used as
a targeted cancer prevention strategy to eradicate
premalignant cells with defined genetic alterations
[8].
Therefore, it is a key question to identify genes
or drugs that have a synthetic lethal interaction
with genes or pathways altered in premalignant
cells, which can provide us with opportunities to
develop synthetic lethality-based targeted cancer
prevention. Selective killing of BRCA-deficient breast
cancer cells by poly (ADP-ribose) polymerase (PARP)
inhibitors highlighted that DNA repair pathways
can be exploited to discover new synthetic lethal
interactions for cancer prevention [9,10].
Breast cancer susceptible proteins BRCA1 and
BRCA2 are required for DNA double-strand break
(DSB) repair by the error-free mechanism of
homologous recombination (HR) through gene
conversion [11-13]. Cells deficient in BRCA1 or
BRCA2 have been found to be100-1000–fold more
sensitive to inhibitors of poly-ADP-ribose polymerase
(PARP) than normal cells [9,10]. The underlying
mechanism stems from a delicate synthetic lethal
effect. PARP is an enzyme that facilitates repair
of single-stranded breaks (SSB). In normal cells,
DNA damage generated by PARP inhibitors is well
tolerated because of functional compensation from
the HR repair pathway. In contrast, HR repair
defective cancer cells, such as BRCA1 or BRCA2
deficient-cells, are unable to cope with this increased
DNA damage and thereby exhibit hypersensitivity
to PARP1 inhibitors [14] . This finding provides a
molecular basis to exploit induced cancer-specific
synthetic lethality by PARP1 inhibitors not limited to
BRCA1 or BRCA2 deficient-cells, but more broadly
applied to all HR deficient cancer cells. BRCA1
and BRCA2 are frequently mutated in familial
breast cancer and ovarian cancer patients. Currently,
multiple studies are testing the preventive effects
of PARP inhibitors in preventing BRCA-associated
breast and ovarian cancers.
It is worth noting that using synthetic lethality
as a promising approach for cancer prevention
might be more readily exploited for germline
mutations that predispose to carcinogenesis such
as mutations of APC and BRCA genes described
above. In contrast, targeting somatic mutations
present in premalignant lesions could be more
challenging. Firstly, the common or frequent
mutations in premalignant lesions are not well-
defined. The next generation sequencing technology
can be a promising approach to identify somatic
aberrations in premalignant lesions, which will help
establish effective genetic interactions to develop
synthetic lethality-based interventions. Importantly,
premalignant cells with a limited number of genetic
alterations represent the most efficient stage during
carcinogenesis for targeted intervention. Thus
targeted chemoprevention using synthetic lethality-
strategies can be very effective at very early stages of
tumorigenesis. Secondly, In order to determine the
efficacy of targeted chemoprevention, it is essential
for us to have an effective screening tool to monitor
the progression of premalignant diseases. Thus, to
develop effective screening methods and to identify
biomarkers are the key steps for the success of this
targeted prevention strategy.
In summary, here we presented studies to
show that it is indeed possible to use synthetic
lethal interactions to develop effective targeted
cancer prevention strategies. Instead of searching
for a universal chemoprevention drug for large
populations of people at relatively low risk, one
promising direction of chemoprevention research
in future is to identify intervention strategies for
subpopulations at high risk of developing cancer
by targeting the genetic alterations in premalignant
lesions, such as using a synthetic lethality as a guide
for drug discovery.
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